Monday, January 8, 2024
December 09 - 12, 2023; San Diego, California and Virtual/Online
New Multiple Myeloma Staging Systems Outperform the Standard
Infection Main Cause of Nonrelapse Death With CAR T Therapy
Sickle Cell CRISPR Therapy May Offer 'Functional Cure'
This Frontline Therapy Is Better in Multiple Myeloma: Study
SCD Mortality Rates Improved for Black Patients in 2010s
No Benefit to Salvage Transplant in R/R Multiple Myeloma
Sickle Cell: Good Outcomes for Haploidentical Transplants
Mantle Cell Lymphoma: Drug Combo Improves PFS
Myeloma: Isatuximab 4-Drug Regimen Boosts MRD Negativity
MRD Status Predicts Transplant Benefit in NPM1-Mutated AML
Measurable Residual Disease-Guided Therapy Promising in CLL
Relapsed DLBCL: Complete Interim Response, SCT Beats CAR T
Distinct Toxicity Profiles for Anti-BCMA Myeloma Therapies
CAR T-Cell Therapy: Cure for Systemic Autoimmune Diseases?
Sickle Cell Gene Therapy 'Truly Transformative'
This Test May Guide AML Therapy for Black Pediatric Patients
In Real World, Patients With Myeloma Have Worse Outcomes
Hematology Is in the Brodsky Family's Blood
ASH 2023
ASH 2023: Equity, Sickle Cell, and Real-Life Outcomes
Medscape Oncology© WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Myelofibrosis Highlights From ASH 2023
Clinical Takeaways in Thrombocytopenia From ASH 2023
ASH 2023: New Geriatric Assessment Tools in DLBCL
Paroxysmal Nocturnal Hemoglobinuria Highlights From ASH 2023
Advances in Acute Lymphoblastic Leukemia From ASH 2023
Chronic Lymphocytic Leukemia Highlights From ASH 2023
ASH 2023: Key Insights on Advances in DLBCL
